Curis (CRIS) Q2 Loss Narrows 66%

Curis (NASDAQ:CRIS), a biotechnology company focused on developing targeted cancer therapies, reported its earnings for the second quarter of 2025 on August 5, 2025. Curis reported a GAAP net loss of $0.68 per share, outperforming the analyst expectation of a $1.36 GAAP loss. Year-over-year, expenses fell sharply, narrowing the net loss compared to the same period in 2024 However, leadership warned that cash levels as of June 30, 2025, are not sufficient to fund operations beyond the first quarter of 2026, and no new financial guidance was provided for the remainder of the year. Source: Analyst estimates for the quarter provided by FactSet. Curis is a biotechnology company specializing in the discovery and development of drugs that target specific cancer pathways. Its pipeline centers on emavusertib, an oral small molecule inhibitor, designed to address a range of blood cancers such as lymphoma and leukemia.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool